首页 > 最新文献

Critical Reviews in Therapeutic Drug Carrier Systems最新文献

英文 中文
Combating HIV Latency: A Review of Innovative Interventions and Nanotechnology-Based Formulations. 抗击艾滋病毒潜伏期:创新干预措施和基于纳米技术的配方综述。
IF 2.5 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2025054733
Divya Dubey, Trinette Fernandes, Prabha Singh

The HIV-1 reservoir is a residual pool of integrated viral genomes that endure in a condition of reversible non-productive infection, notwithstanding suppressive antiretroviral therapy's ability to successfully inhibit HIV-1 replication and evolution. Individual T cells are capable of developing a latent infection due to HIV-1. Even in patients receiving highly effective marketed antiretroviral medication, latent virus survives perpetually in memory T cells and exhibit atypical cellular signaling and metabolic dysfunction, which can cause minor to severe cellular and systemic comorbidities. These include lymphocytic, cardiac, renal, hepatic, and pulmonary dysfunctions as well as genomic DNA damage, telomere attrition, and mitochondrial dysfunction. This latent reservoir is understood to be a substantial challenge for treating HIV-1 infection. The presence of a latent reservoir for HIV-1 can be used to explain the extremely low levels of viremia in patients undergoing antiretroviral therapy. In an effort to eradicate the latent reservoir, several methods are being investigated for reactivating dormant viruses. This review concentrates on figuring out how to awaken latent HIV-1 by adding detailed information about drugs and formulations discovered for latent HIV. This work may provoke the thoughts related for discovering many more promising drugs, and targeting strategies to totally eradicate the HIV.

尽管抑制性抗逆转录病毒疗法能够成功地抑制HIV-1的复制和进化,但HIV-1储存库是一个整合病毒基因组的残余库,它们在可逆的非生产性感染条件下持续存在。单个T细胞能够由于HIV-1而产生潜伏性感染。即使在接受高效抗逆转录病毒上市药物治疗的患者中,潜伏病毒也会在记忆T细胞中永久存活,并表现出非典型的细胞信号传导和代谢功能障碍,这可能导致轻微至严重的细胞和全身合并症。这些包括淋巴细胞、心脏、肾脏、肝脏和肺功能障碍以及基因组DNA损伤、端粒磨损和线粒体功能障碍。这一潜伏病毒库被认为是治疗HIV-1感染的一个重大挑战。HIV-1潜伏库的存在可以用来解释在接受抗逆转录病毒治疗的患者中病毒血症水平极低。为了根除潜伏的病毒库,正在研究几种重新激活休眠病毒的方法。这篇综述的重点是如何唤醒潜伏的HIV-1,并增加了针对潜伏HIV的药物和配方的详细信息。这项工作可能会激发人们对发现更多有前途的药物和彻底根除艾滋病毒的靶向策略的思考。
{"title":"Combating HIV Latency: A Review of Innovative Interventions and Nanotechnology-Based Formulations.","authors":"Divya Dubey, Trinette Fernandes, Prabha Singh","doi":"10.1615/CritRevTherDrugCarrierSyst.2025054733","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2025054733","url":null,"abstract":"<p><p>The HIV-1 reservoir is a residual pool of integrated viral genomes that endure in a condition of reversible non-productive infection, notwithstanding suppressive antiretroviral therapy's ability to successfully inhibit HIV-1 replication and evolution. Individual T cells are capable of developing a latent infection due to HIV-1. Even in patients receiving highly effective marketed antiretroviral medication, latent virus survives perpetually in memory T cells and exhibit atypical cellular signaling and metabolic dysfunction, which can cause minor to severe cellular and systemic comorbidities. These include lymphocytic, cardiac, renal, hepatic, and pulmonary dysfunctions as well as genomic DNA damage, telomere attrition, and mitochondrial dysfunction. This latent reservoir is understood to be a substantial challenge for treating HIV-1 infection. The presence of a latent reservoir for HIV-1 can be used to explain the extremely low levels of viremia in patients undergoing antiretroviral therapy. In an effort to eradicate the latent reservoir, several methods are being investigated for reactivating dormant viruses. This review concentrates on figuring out how to awaken latent HIV-1 by adding detailed information about drugs and formulations discovered for latent HIV. This work may provoke the thoughts related for discovering many more promising drugs, and targeting strategies to totally eradicate the HIV.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"42 5","pages":"55-99"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in Skin Cancer Prevention and Treatment: Harnessing Technology, Natural Therapies, and Emerging Diagnostic Approaches. 皮肤癌预防和治疗的进展:利用技术、自然疗法和新兴诊断方法。
IF 2.5 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2025053255
Roshan Kumar Gupta, Lensi Parvadiya, Kiran Dudhat

Skin cancer is one of the most prevalent malignancies globally, with rising incidence rates driven by environmental and genetic factors. This manuscript aims to explore recent advancements in the prevention and treatment of skin cancer, focusing on the integration of emerging technologies, plant-based therapies, and innovative diagnostic approaches. Exposure to ultraviolet (UV) radiation is the primary environmental risk factor for skin cancer, contributing to both melanoma and non-melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Advances in technology, such as AI-driven diagnostic tools and non-invasive imaging techniques, are transforming early detection and risk assessment. Additionally, the role of genetic factors, such as p53 mutations in the development of SCC, is highlighted, emphasizing the importance of molecular diagnostics in guiding treatment strategies. In the realm of therapeutics, plant-based compounds are gaining traction for their anti-cancer properties. Natural agents such as polyphenols and flavonoids exhibit UV-protective and anti-carcinogenic effects, offering promising adjuncts to conventional treatments. Moreover, innovative treatment modalities, including immunotherapy and nanotechnology-based drug delivery systems, are being explored to enhance the efficacy of traditional chemotherapies while minimizing side effects. This article comprehensively reviews the types and classifications of skin cancer, the role of biological and non-biological risk factors, and cutting-edge prevention strategies. It also delves into the potential of plant-based therapies and the emerging role of nanotechnology and advanced diagnostic techniques in skin cancer management. By examining these novel approaches, the manuscript offers a forward-looking perspective on improving early detection, enhancing treatment outcomes, and reducing the global burden of skin cancer. These insights could pave the way for integrating innovative therapies and technologies into clinical practice, facilitating more effective skin cancer management.

皮肤癌是全球最常见的恶性肿瘤之一,受环境和遗传因素的影响,发病率不断上升。本文旨在探讨皮肤癌预防和治疗的最新进展,重点是新兴技术、植物性治疗和创新诊断方法的整合。暴露于紫外线(UV)辐射是皮肤癌的主要环境危险因素,有助于黑色素瘤和非黑色素瘤皮肤癌(NMSC),包括鳞状细胞癌(SCC)和基底细胞癌(BCC)。人工智能驱动的诊断工具和非侵入性成像技术等技术进步正在改变早期发现和风险评估。此外,遗传因素如p53突变在SCC发展中的作用也得到了强调,强调了分子诊断在指导治疗策略中的重要性。在治疗领域,植物基化合物因其抗癌特性而受到关注。天然药物如多酚和类黄酮具有防紫外线和抗癌作用,为传统治疗提供了有希望的辅助手段。此外,正在探索创新的治疗方式,包括免疫疗法和基于纳米技术的药物输送系统,以提高传统化疗的疗效,同时最大限度地减少副作用。本文全面综述了皮肤癌的类型和分类,生物和非生物危险因素的作用,以及最新的预防策略。它还深入研究了植物疗法的潜力,纳米技术和先进诊断技术在皮肤癌管理中的新兴作用。通过研究这些新方法,该手稿为改善早期发现、提高治疗效果和减少皮肤癌的全球负担提供了前瞻性的观点。这些见解可以为将创新疗法和技术整合到临床实践中铺平道路,促进更有效的皮肤癌管理。
{"title":"Advancements in Skin Cancer Prevention and Treatment: Harnessing Technology, Natural Therapies, and Emerging Diagnostic Approaches.","authors":"Roshan Kumar Gupta, Lensi Parvadiya, Kiran Dudhat","doi":"10.1615/CritRevTherDrugCarrierSyst.2025053255","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2025053255","url":null,"abstract":"<p><p>Skin cancer is one of the most prevalent malignancies globally, with rising incidence rates driven by environmental and genetic factors. This manuscript aims to explore recent advancements in the prevention and treatment of skin cancer, focusing on the integration of emerging technologies, plant-based therapies, and innovative diagnostic approaches. Exposure to ultraviolet (UV) radiation is the primary environmental risk factor for skin cancer, contributing to both melanoma and non-melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Advances in technology, such as AI-driven diagnostic tools and non-invasive imaging techniques, are transforming early detection and risk assessment. Additionally, the role of genetic factors, such as p53 mutations in the development of SCC, is highlighted, emphasizing the importance of molecular diagnostics in guiding treatment strategies. In the realm of therapeutics, plant-based compounds are gaining traction for their anti-cancer properties. Natural agents such as polyphenols and flavonoids exhibit UV-protective and anti-carcinogenic effects, offering promising adjuncts to conventional treatments. Moreover, innovative treatment modalities, including immunotherapy and nanotechnology-based drug delivery systems, are being explored to enhance the efficacy of traditional chemotherapies while minimizing side effects. This article comprehensively reviews the types and classifications of skin cancer, the role of biological and non-biological risk factors, and cutting-edge prevention strategies. It also delves into the potential of plant-based therapies and the emerging role of nanotechnology and advanced diagnostic techniques in skin cancer management. By examining these novel approaches, the manuscript offers a forward-looking perspective on improving early detection, enhancing treatment outcomes, and reducing the global burden of skin cancer. These insights could pave the way for integrating innovative therapies and technologies into clinical practice, facilitating more effective skin cancer management.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"42 5","pages":"1-54"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Review on Nanophytomedicines in the Treatment of Oral Cancer: Recent Trends and Treatment Prospects. 纳米植物药在口腔癌治疗中的应用综述:最新趋势与治疗前景》。
IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.v42.i1.30
Neha P Shukla, Giftson J Senapathy

Cancer is one of the major life-threatening diseases in the world and oral cancer is the 8th most common type of deadly cancers in Asian countries. Despite many causes, tobacco is the main causative agent as 90% of oral cancer cases were due to daily consumption of tobacco and its products. The major drawback of the conventional therapies for oral cancer including chemotherapy, surgery and radiotherapy or combination of these is the dose limiting toxicity. Developments in technology and research led to new innovative discoveries in cancer treatments. In the past few decades, increased attention has been given to researches in alternative cancer treatment strategies using plants and plant products. Recently many anticancer drugs from natural products or phytochemicals were approved internationally. Due to the low bioavailability and poor solubility of phytochemicals, various research works on nano-carrier based drug delivery systems were exploited in the recent past to make them as promising anticancer agents. In the current review, an overview of oral cancer and its treatment, risk factors, missing links of conventional therapies, contribution of nanotechnology in cancer treatment and research on phytochemical based drug treatment and different polymeric nanoparticles were discussed briefly. The future prospects for the use of various types of polymeric nanoparticles applied in the diagnosis and treatment of oral cancer were also mentioned. The major concern of this review is to give the reader a better understanding on various types of treatment for oral cancer.

癌症是世界上威胁生命的主要疾病之一,而在亚洲国家,口腔癌是第 8 种最常见的致命癌症。尽管诱因很多,但烟草是主要的致病因素,因为 90% 的口腔癌病例都是由于日常消费烟草及其产品所致。传统的口腔癌疗法,包括化疗、手术和放疗或这些疗法的组合,其主要缺点是剂量限制性毒性。技术和研究的发展带来了癌症治疗的新发现。在过去的几十年里,人们越来越关注利用植物和植物产品替代癌症治疗策略的研究。最近,国际上批准了许多来自天然产品或植物化学物质的抗癌药物。由于植物化学物质的生物利用度低、溶解性差,近年来,人们对基于纳米载体的给药系统进行了各种研究,使其成为有前景的抗癌药物。本综述概述了口腔癌及其治疗、风险因素、传统疗法的缺失环节、纳米技术在癌症治疗中的贡献以及基于植物化学药物治疗和不同聚合物纳米粒子的研究。此外,还提到了在口腔癌诊断和治疗中使用各种聚合物纳米粒子的未来前景。本综述的主要目的是让读者更好地了解各类口腔癌治疗方法。
{"title":"Current Review on Nanophytomedicines in the Treatment of Oral Cancer: Recent Trends and Treatment Prospects.","authors":"Neha P Shukla, Giftson J Senapathy","doi":"10.1615/CritRevTherDrugCarrierSyst.v42.i1.30","DOIUrl":"10.1615/CritRevTherDrugCarrierSyst.v42.i1.30","url":null,"abstract":"<p><p>Cancer is one of the major life-threatening diseases in the world and oral cancer is the 8th most common type of deadly cancers in Asian countries. Despite many causes, tobacco is the main causative agent as 90% of oral cancer cases were due to daily consumption of tobacco and its products. The major drawback of the conventional therapies for oral cancer including chemotherapy, surgery and radiotherapy or combination of these is the dose limiting toxicity. Developments in technology and research led to new innovative discoveries in cancer treatments. In the past few decades, increased attention has been given to researches in alternative cancer treatment strategies using plants and plant products. Recently many anticancer drugs from natural products or phytochemicals were approved internationally. Due to the low bioavailability and poor solubility of phytochemicals, various research works on nano-carrier based drug delivery systems were exploited in the recent past to make them as promising anticancer agents. In the current review, an overview of oral cancer and its treatment, risk factors, missing links of conventional therapies, contribution of nanotechnology in cancer treatment and research on phytochemical based drug treatment and different polymeric nanoparticles were discussed briefly. The future prospects for the use of various types of polymeric nanoparticles applied in the diagnosis and treatment of oral cancer were also mentioned. The major concern of this review is to give the reader a better understanding on various types of treatment for oral cancer.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"42 1","pages":"89-118"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the Molecular Targets in Non-Small-Cell Lung Cancer and a Nanomedicine-Based Remedy. 解锁非小细胞肺癌的分子靶点和基于纳米医学的治疗方法。
IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2024053289
Kangkan Sarma, Md Habban Akhter, Amnah Alalmaie, Irfan Ahmad, Mohd Nazam Ansari, Habibullah Khalilullah, Syeda Ayesha Farhana, Shalam M Hussain, Adel M Aljadaan

Lung cancer has the second highest occurrence and lowest survival rate among all cancers and incidence rates are increasing. From the tumor milieu, tumors exude chemokines and cytokines that hassle the pulmonary drug administration hinders the success of treatment. A few mutations lead to generation of lungs cancer. It has prominent levels of mutated genes such as TP53, KRAS, MET, and EGFR. Various molecular pathways involved in causing lung cancer such as PTEN/PI3K/AKT pathway, JAK/STAT pathways, RAF-MEK-ERK, PI3K-AKT-mTOR, and RALGDS-RA, PI3K, AKT, and PI3K/AKT/mTOR pathway. Inhibition of such biological pathway through active targeting, using various biological inhibitors, and blockers could help in treating and recurrence of lungs tumor. The conventional therapeutic modalities concomitant with personalized genomic nanomedicine can have potential in improving treatment regimen. This study explored the different genomic changes that occur due to the prime etiological factors, their reported treatment profile, and nanocarrier mediated therapeutic strategy by targeting tumor microenvironment (TME). Nanocarriers confront multiple obstacles in their journey to the TME therapeutic approach as leaky vasculature, large fenestration, and usually carried off from immune system and phagocytosis process. However, formulators designed a bio-functionalized carrier that enable to evade opsonization, escape immune system, modulate TME, identify reticuloendothelial system, and thus facilitates biological interaction, and enhance cellular uptake.

肺癌在所有癌症中发病率第二高,存活率最低,而且发病率还在增加。从肿瘤环境来看,肿瘤会分泌出趋化因子和细胞因子,这些因子会阻碍肺部药物的施用,从而阻碍治疗的成功。一些突变会导致肺癌的产生。它有显著水平的突变基因,如TP53, KRAS, MET和EGFR。参与肺癌发生的各种分子通路,如PTEN/PI3K/AKT通路、JAK/STAT通路、RAF-MEK-ERK、PI3K-AKT-mTOR、RALGDS-RA、PI3K、AKT、PI3K/AKT/mTOR通路。通过主动靶向、使用多种生物抑制剂和阻滞剂抑制这一生物通路,有助于肺肿瘤的治疗和复发。传统的治疗方式与个性化的基因组纳米药物相结合,在改善治疗方案方面具有潜力。本研究探讨了因主要病因而发生的不同基因组变化,其报道的治疗概况,以及靶向肿瘤微环境(TME)的纳米载体介导的治疗策略。纳米载体在进入TME治疗途径的过程中面临着许多障碍,如血管渗漏、开窗大、通常从免疫系统和吞噬过程中被带走。然而,配方师设计了一种生物功能化载体,能够逃避调理,逃避免疫系统,调节TME,识别网状内皮系统,从而促进生物相互作用,增强细胞摄取。
{"title":"Unlocking the Molecular Targets in Non-Small-Cell Lung Cancer and a Nanomedicine-Based Remedy.","authors":"Kangkan Sarma, Md Habban Akhter, Amnah Alalmaie, Irfan Ahmad, Mohd Nazam Ansari, Habibullah Khalilullah, Syeda Ayesha Farhana, Shalam M Hussain, Adel M Aljadaan","doi":"10.1615/CritRevTherDrugCarrierSyst.2024053289","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2024053289","url":null,"abstract":"<p><p>Lung cancer has the second highest occurrence and lowest survival rate among all cancers and incidence rates are increasing. From the tumor milieu, tumors exude chemokines and cytokines that hassle the pulmonary drug administration hinders the success of treatment. A few mutations lead to generation of lungs cancer. It has prominent levels of mutated genes such as TP53, KRAS, MET, and EGFR. Various molecular pathways involved in causing lung cancer such as PTEN/PI3K/AKT pathway, JAK/STAT pathways, RAF-MEK-ERK, PI3K-AKT-mTOR, and RALGDS-RA, PI3K, AKT, and PI3K/AKT/mTOR pathway. Inhibition of such biological pathway through active targeting, using various biological inhibitors, and blockers could help in treating and recurrence of lungs tumor. The conventional therapeutic modalities concomitant with personalized genomic nanomedicine can have potential in improving treatment regimen. This study explored the different genomic changes that occur due to the prime etiological factors, their reported treatment profile, and nanocarrier mediated therapeutic strategy by targeting tumor microenvironment (TME). Nanocarriers confront multiple obstacles in their journey to the TME therapeutic approach as leaky vasculature, large fenestration, and usually carried off from immune system and phagocytosis process. However, formulators designed a bio-functionalized carrier that enable to evade opsonization, escape immune system, modulate TME, identify reticuloendothelial system, and thus facilitates biological interaction, and enhance cellular uptake.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"42 4","pages":"1-58"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing Microemulsion based Therapeutic Drug Delivery: Exploring Surfactants, Co-surfactants, and Quality by Design Strategies within Pseudo-ternary Phase Diagrams 增强基于微乳液的治疗性给药:探索伪三元相图中的表面活性剂、辅助表面活性剂和质量设计策略
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-01 DOI: 10.1615/critrevtherdrugcarriersyst.2024053427
Abhishek Bamanna, Anjali Rajora, Kalpana Nagpal
Microemulsions are thermodynamically stable, clear and homogeneous mixtures of oil, water, and surfactants that have garnered significant attention in various industrial and biomedical applications. The basic components of microemulsions are oil, water, and surfactant, and their composition ratios play a crucial role in determining their properties and stability. Factors such as the type of surfactant, oil, and water used, temperature, and the presence of cosurfactants can greatly influence the formation, stability and properties of microemulsions. These are appropriate for use in drug delivery applications because to their physicochemical characteristics, which include small droplet size, large interfacial area, and good solubilization capacity for both hydrophilic and hydrophobic drugs with significant improvement in their biological activity. The theories of microemulsion and the role of phase diagrams in microemulsion formation and various components for choice of surfactant and co-surfactant are explained. Recent advancements in the preparation and characterization techniques of microemulsion, ranging from visual inspection to the phase behaviour studies and advanced spectroscopic techniques, with a focus on potential of microemulsion in drug delivery along with microemulsion-based drug candidates that are most commonly used for its formulation are also discussed. The review helps in understanding how different excipients affect the release of the active pharmaceutical ingredient. The quality by design approach utilized for optimization of microemulsions is also discussed.
微乳剂是一种热力学稳定、透明且均匀的油、水和表面活性剂混合物,在各种工业和生物医学应用中备受关注。微乳液的基本成分是油、水和表面活性剂,它们的组成比例在决定微乳液的性质和稳定性方面起着至关重要的作用。所使用的表面活性剂、油和水的类型、温度以及共表面活性剂的存在等因素会极大地影响微乳剂的形成、稳定性和特性。微乳剂的理化特性包括液滴体积小、界面面积大、对亲水性和疏水性药物均有良好的溶解能力,可显著提高药物的生物活性,因此适合用于药物输送。本文阐述了微乳液的理论、相图在微乳液形成中的作用以及选择表面活性剂和助表面活性剂的各种因素。此外,还讨论了微乳液制备和表征技术的最新进展,包括从目视检查到相行为研究和先进的光谱技术,重点介绍了微乳液在给药方面的潜力,以及最常用于制剂的基于微乳液的候选药物。该综述有助于了解不同辅料如何影响活性药物成分的释放。此外,还讨论了用于优化微乳剂的质量设计方法。
{"title":"Enhancing Microemulsion based Therapeutic Drug Delivery: Exploring Surfactants, Co-surfactants, and Quality by Design Strategies within Pseudo-ternary Phase Diagrams","authors":"Abhishek Bamanna, Anjali Rajora, Kalpana Nagpal","doi":"10.1615/critrevtherdrugcarriersyst.2024053427","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2024053427","url":null,"abstract":"Microemulsions are thermodynamically stable, clear and homogeneous mixtures of oil, water, and surfactants that have garnered significant attention in various industrial and biomedical applications. The basic components of microemulsions are oil, water, and surfactant, and their composition ratios play a crucial role in determining their properties and stability. Factors such as the type of surfactant, oil, and water used, temperature, and the presence of cosurfactants can greatly influence the formation, stability and properties of microemulsions. These are appropriate for use in drug delivery applications because to their physicochemical characteristics, which include small droplet size, large interfacial area, and good solubilization capacity for both hydrophilic and hydrophobic drugs with significant improvement in their biological activity. The theories of microemulsion and the role of phase diagrams in microemulsion formation and various components for choice of surfactant and co-surfactant are explained. Recent advancements in the preparation and characterization techniques of microemulsion, ranging from visual inspection to the phase behaviour studies and advanced spectroscopic techniques, with a focus on potential of microemulsion in drug delivery along with microemulsion-based drug candidates that are most commonly used for its formulation are also discussed. The review helps in understanding how different excipients affect the release of the active pharmaceutical ingredient. The quality by design approach utilized for optimization of microemulsions is also discussed.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"9 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142222521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NOVEL DRUG DELIVERY TOOLS FOR BETTER PERMEATION AND SKIN CANCER TREATMENT 新型给药工具,提高渗透性和皮肤癌治疗效果
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-01 DOI: 10.1615/critrevtherdrugcarriersyst.2024047670
Kajal Chaudhary, Anjali Rajora
Skin cancer stands as a challenging global health concern, necessitating innovative approaches to cure deficiencies within traditional therapeutic modalities. While conventional drug delivery methods through injection or oral administration have long prevailed, the emergence of topical drug administration presents a compelling alternative. The skin, aside from offering a swift and painless procedure, serves as a reservoir, maintaining drug efficacy over extended durations. This comprehensive review seeks to shed light on the potential of nanotechnology as a promising avenue for efficacious cancer treatment, with a particular emphasis on skin cancer. Additionally, it underscores the transdermal approach as a viable strategy for addressing various types of cancer. This work also explores into the delivery of peptides and proteins along with in-depth explanations of different delivery systems currently under investigation for localized skin cancer treatment. Furthermore, the review discusses the formidable challenges that must be surmounted before these innovations can find their way into clinical practice, offering a roadmap for future research and therapeutic development.
皮肤癌是一个具有挑战性的全球健康问题,需要采用创新方法来治疗传统治疗方法的不足。长期以来,传统的注射或口服给药方法一直占主导地位,而外用给药方法的出现则提供了一种令人信服的替代方法。皮肤不仅可以提供快速、无痛的治疗过程,还可以作为药物的储存库,在较长的时间内保持药效。本综述旨在阐明纳米技术作为一种有效治疗癌症的途径所具有的潜力,尤其侧重于皮肤癌。此外,它还强调透皮疗法是治疗各类癌症的可行策略。这部著作还探讨了多肽和蛋白质的输送,并深入解释了目前正在研究的用于局部皮肤癌治疗的不同输送系统。此外,该综述还讨论了在这些创新进入临床实践之前必须克服的严峻挑战,为未来的研究和治疗开发提供了路线图。
{"title":"NOVEL DRUG DELIVERY TOOLS FOR BETTER PERMEATION AND SKIN CANCER TREATMENT","authors":"Kajal Chaudhary, Anjali Rajora","doi":"10.1615/critrevtherdrugcarriersyst.2024047670","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2024047670","url":null,"abstract":"Skin cancer stands as a challenging global health concern, necessitating innovative approaches to cure deficiencies within traditional therapeutic modalities. While conventional drug delivery methods through injection or oral administration have long prevailed, the emergence of topical drug administration presents a compelling alternative. The skin, aside from offering a swift and painless procedure, serves as a reservoir, maintaining drug efficacy over extended durations. This comprehensive review seeks to shed light on the potential of nanotechnology as a promising avenue for efficacious cancer treatment, with a particular emphasis on skin cancer. Additionally, it underscores the transdermal approach as a viable strategy for addressing various types of cancer. This work also explores into the delivery of peptides and proteins along with in-depth explanations of different delivery systems currently under investigation for localized skin cancer treatment. Furthermore, the review discusses the formidable challenges that must be surmounted before these innovations can find their way into clinical practice, offering a roadmap for future research and therapeutic development.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"12 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141504150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanobiocatalysts and Nanozymes: Enzyme-Inspired Nanomaterials for Industrial and Biomedical Applications 纳米生物催化剂和纳米酶:用于工业和生物医学应用的酶启发纳米材料
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 DOI: 10.1615/critrevtherdrugcarriersyst.2024051171
Sarika Gupta, Meenu Kumari, Koyel Panja, Priyanka Bajaj, Kalpana Nagpal
Enzymes play a pivotal role in the human body, but their potential is not limited to just that. Scientists have successfully modified these enzymes as nanobiocatalysts or nanozymes for industrial or commercial use, either in the food, medicine, biotech, or even textile industries. These nanobiocatalysts and nanozymes offer several advantages over enzymes, like better stability, improved shelf-life, increased percentage yield, and reuse potential, which is very difficult with normal enzymes. The various techniques of NBC synthesis using immobilization techniques like adsorption, covalent binding, affinity immobilization, and entrapment methods are briefly discussed. The enzymes are either entrapped or adsorbed on the nanocarrier matrices, which can be nanofibers, nanoporous carriers, or nanocontainers as nanobiocatalysts. We also highlight the challenges the nanobiocatalyst overcomes in the industrial production of some drugs like sitagliptin, montelukast, pregabalin, and atorvastatin. Also, the inactivation of an organophosphate or opioid poisoning treating agent, SSOPOX nanohybrid, is discussed in this paper. Nanozymes are intrinsic enzyme-like compounds, and they also show wide application in themselves. Their GQD/AGNP nanohybrid shows antibacterial potential; they can also be utilized in optical sensing to detect small molecules, ions, nucleic acids, proteins, and cancer cells. In this paper, various applications of these NBCs have been discussed, and their potential applications with examples are also mentioned.
酶在人体中发挥着举足轻重的作用,但其潜力并不仅限于此。科学家们已经成功地将这些酶改造成纳米生物催化剂或纳米酶,用于食品、医药、生物技术甚至纺织工业等工业或商业用途。与酶相比,这些纳米生物催化剂和纳米酶具有一些优势,如稳定性更好、保质期更长、产量百分比更高以及具有重复使用的潜力,而这是普通酶很难做到的。本文简要讨论了利用吸附、共价结合、亲和固定和夹持等固定化技术合成 NBC 的各种技术。酶被夹带或吸附在纳米载体基质上,纳米载体可以是纳米纤维、纳米多孔载体或纳米容器,作为纳米生物催化剂。我们还重点介绍了纳米生物催化剂在西格列汀、孟鲁司特、普瑞巴林和阿托伐他汀等药物的工业化生产中所克服的挑战。此外,本文还讨论了有机磷或阿片类中毒治疗药物 SSOPOX 纳米混合体的灭活问题。纳米酶是一种固有的类酶化合物,其本身也具有广泛的应用前景。其 GQD/AGNP 纳米杂化物具有抗菌潜力,还可用于光学传感,检测小分子、离子、核酸、蛋白质和癌细胞。本文讨论了这些 NBC 的各种应用,并举例说明了它们的潜在应用。
{"title":"Nanobiocatalysts and Nanozymes: Enzyme-Inspired Nanomaterials for Industrial and Biomedical Applications","authors":"Sarika Gupta, Meenu Kumari, Koyel Panja, Priyanka Bajaj, Kalpana Nagpal","doi":"10.1615/critrevtherdrugcarriersyst.2024051171","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2024051171","url":null,"abstract":"Enzymes play a pivotal role in the human body, but their potential is not limited to just that. Scientists have successfully modified these enzymes as nanobiocatalysts or nanozymes for industrial or commercial use, either in the food, medicine, biotech, or even textile industries. These nanobiocatalysts and nanozymes offer several advantages over enzymes, like better stability, improved shelf-life, increased percentage yield, and reuse potential, which is very difficult with normal enzymes. The various techniques of NBC synthesis using immobilization techniques like adsorption, covalent binding, affinity immobilization, and entrapment methods are briefly discussed. The enzymes are either entrapped or adsorbed on the nanocarrier matrices, which can be nanofibers, nanoporous carriers, or nanocontainers as nanobiocatalysts. We also highlight the challenges the nanobiocatalyst overcomes in the industrial production of some drugs like sitagliptin, montelukast, pregabalin, and atorvastatin. Also, the inactivation of an organophosphate or opioid poisoning treating agent, SSOPOX nanohybrid, is discussed in this paper. Nanozymes are intrinsic enzyme-like compounds, and they also show wide application in themselves. Their GQD/AGNP nanohybrid shows antibacterial potential; they can also be utilized in optical sensing to detect small molecules, ions, nucleic acids, proteins, and cancer cells. In this paper, various applications of these NBCs have been discussed, and their potential applications with examples are also mentioned.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"160 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141147309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the Challenges of 3D Printing Personalized Medicine in Space Explorations: A Comprehensive Review 在太空探索中驾驭 3D 打印个性化医疗的挑战:全面回顾
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-01 DOI: 10.1615/critrevtherdrugcarriersyst.2024051126
PRAKASH KATAKAM, Madhavi Lakshmi Ratna Bhavaraju, Tanniru Venkata Narayana, Koushik Bhandari, Nagarajan Sriram, Vidya Sagar Sisinty, Shanta Kumari Adiki
Space exploration has undergone a paradigm shift in recent years, with a growing emphasis on long-duration missions and human habitation on other celestial bodies. Private aerospace businesses are at the forefront of advancing the next iteration of spacecraft, encompassing a wide range of applications such as deep space exploration (e.g., SpaceX) and cost-effective satellite deployments (e.g., Rocketlab). One of the critical challenges associated with prolonged space missions is the provision of personalized medical care. 3D printing technology has emerged as a potential solution, enabling the on-demand production of personalized medical devices and medications. However, the unique conditions of space pose substantial challenges to the successful implementation of 3D printing for personalized medicine. Tremendous scope for research exists in terms of resource utilization and waste management in space ecosystem, robotic and AI enabled tool utilization, remote operability, interplanetary travel, space education and training tools, digital twins, space tourism and in many other aspects of 3D printing for personalized medicine in space explorations.
近年来,太空探索的模式发生了转变,越来越强调长期飞行任务和人类在其他天体上的居住。私营航空航天企业走在推进下一代航天器的最前沿,包括深空探索(如 SpaceX)和具有成本效益的卫星部署(如 Rocketlab)等广泛应用。与长期太空任务相关的关键挑战之一是提供个性化医疗服务。三维打印技术已成为一种潜在的解决方案,可按需生产个性化医疗设备和药物。然而,独特的太空条件对成功实施个性化医疗 3D 打印技术构成了巨大挑战。在太空生态系统的资源利用和废物管理、机器人和人工智能工具的利用、远程可操作性、星际旅行、太空教育和培训工具、数字双胞胎、太空旅游以及 3D 打印用于太空探索中的个性化医疗的许多其他方面,都存在巨大的研究空间。
{"title":"Navigating the Challenges of 3D Printing Personalized Medicine in Space Explorations: A Comprehensive Review","authors":"PRAKASH KATAKAM, Madhavi Lakshmi Ratna Bhavaraju, Tanniru Venkata Narayana, Koushik Bhandari, Nagarajan Sriram, Vidya Sagar Sisinty, Shanta Kumari Adiki","doi":"10.1615/critrevtherdrugcarriersyst.2024051126","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2024051126","url":null,"abstract":"Space exploration has undergone a paradigm shift in recent years, with a growing emphasis on long-duration missions and human habitation on other celestial bodies. Private aerospace businesses are at the forefront of advancing the next iteration of spacecraft, encompassing a wide range of applications such as deep space exploration (e.g., SpaceX) and cost-effective satellite deployments (e.g., Rocketlab). One of the critical challenges associated with prolonged space missions is the provision of personalized medical care. 3D printing technology has emerged as a potential solution, enabling the on-demand production of personalized medical devices and medications. However, the unique conditions of space pose substantial challenges to the successful implementation of 3D printing for personalized medicine. Tremendous scope for research exists in terms of resource utilization and waste management in space ecosystem, robotic and AI enabled tool utilization, remote operability, interplanetary travel, space education and training tools, digital twins, space tourism and in many other aspects of 3D printing for personalized medicine in space explorations.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"27 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Conventional to Novel Drug Delivery Systems for Meloxicam: A Systematic Review 美洛昔康的传统给药系统到新型给药系统:系统综述
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-01 DOI: 10.1615/critrevtherdrugcarriersyst.2024048988
Manjusha Annaji, Nur Mita, Jessica Heard, Xuejia Kang, Ishwor Poudel, Sai H.S. Boddu, Amit K. Tiwari, R. Jayachandra Babu
Meloxicam, a selective COX-2 inhibitor, has demonstrated clinical effectiveness in managing inflammation and acute pain. Although available in oral formulations such as capsules, tablets, and suspension, frequent administration is necessary to maintain therapeutic efficacy, which can increase adverse effects and patient non-compliance. To address these issues, several sustained drug delivery strategies such as oral, transdermal, transmucosal, injectable, implantable drug delivery systems have been developed for meloxicam. These sustained drug delivery strategies have the potential to improve the therapeutic efficacy and safety profile of meloxicam by reducing the frequency of dosing and associated gastrointestinal side effects. The choice of drug delivery system will depend on the desired release profile, the target site of inflammation, and the mode of administration. Overall, meloxicam sustained delivery systems offer better patient compliance, and reduce side effects, thereby improving the clinical applications of this drug. Herein, we discuss in detail the different strategies for the sustained delivery of meloxicam.
美洛昔康是一种选择性 COX-2 抑制剂,在治疗炎症和急性疼痛方面具有显著的临床疗效。虽然美洛昔康有胶囊、片剂和混悬剂等口服制剂,但必须频繁给药才能维持疗效,这可能会增加不良反应和患者的不依从性。为解决这些问题,美洛昔康已开发出多种持续给药策略,如口服、透皮、透粘膜、注射和植入式给药系统。这些持续给药策略有可能通过减少给药次数和相关的胃肠道副作用来提高美洛昔康的疗效和安全性。给药系统的选择取决于所需的释放曲线、目标炎症部位和给药方式。总之,美洛昔康持续给药系统能使患者更好地遵从医嘱,减少副作用,从而改善该药物的临床应用。在此,我们将详细讨论美洛昔康持续给药的不同策略。
{"title":"From Conventional to Novel Drug Delivery Systems for Meloxicam: A Systematic Review","authors":"Manjusha Annaji, Nur Mita, Jessica Heard, Xuejia Kang, Ishwor Poudel, Sai H.S. Boddu, Amit K. Tiwari, R. Jayachandra Babu","doi":"10.1615/critrevtherdrugcarriersyst.2024048988","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2024048988","url":null,"abstract":"Meloxicam, a selective COX-2 inhibitor, has demonstrated clinical effectiveness in managing inflammation and acute pain. Although available in oral formulations such as capsules, tablets, and suspension, frequent administration is necessary to maintain therapeutic efficacy, which can increase adverse effects and patient non-compliance. To address these issues, several sustained drug delivery strategies such as oral, transdermal, transmucosal, injectable, implantable drug delivery systems have been developed for meloxicam. These sustained drug delivery strategies have the potential to improve the therapeutic efficacy and safety profile of meloxicam by reducing the frequency of dosing and associated gastrointestinal side effects. The choice of drug delivery system will depend on the desired release profile, the target site of inflammation, and the mode of administration. Overall, meloxicam sustained delivery systems offer better patient compliance, and reduce side effects, thereby improving the clinical applications of this drug. Herein, we discuss in detail the different strategies for the sustained delivery of meloxicam.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"16 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139956067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Path of Novelty from Nanoparticles to Nanobots: Theragnostic Approach for Targeting Cancer Therapy. 从纳米粒子到纳米机器人的创新之路:癌症靶向治疗的热诊断方法。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023046674
Gursharanpreet Kaur, Bhawna Khanna, Mohammed Yusuf, Akanksha Sharma, Akhil Khajuria, Hema K Alajangi, Pradeep K Jaiswal, Mandip Sachdeva, Ravi Pratap Barnwal, Gurpal Singh

Pharmaceutical development of cancer therapeutics is a dynamic area of research. Even after decades of intensive work, cancer continues to be a dreadful disease with an ever-increasing global incidence. The progress of nanotechnology in cancer research has overcome inherent limitations in conventional cancer chemotherapy and fulfilled the need for target-specific drug carriers. Nanotechnology uses the altered patho-physiological microenvironment of malignant cells and offers various advantages like improved solubility, reduced toxicity, prolonged drug circulation with controlled release, circumventing multidrug resistance, and enhanced biodistribution. Early cancer detection has a crucial role in selecting the best drug regime, thus, diagnosis and therapeutics go hand in hand. Furthermore, nanobots are an amazing possibility and promising innovation with numerous significant applications, particularly in fighting cancer and cleaning out blood vessels. Nanobots are tiny robots, ranging in size from 1 to 100 nm. Moreover, the nanobots would work similarly to white blood cells, watching the bloodstream and searching for indications of distress. This review articulates the evolution of various organic and inorganic nanoparticles and nanobots used as therapeutics, along with their pros and cons. It also highlights the shift in diagnostics from conventional methods to more advanced techniques. This rapidly growing domain is providing more space for engineering desired nanoparticles that can show miraculous results in therapeutic and diagnostic trials.

癌症治疗药物的研发是一个充满活力的研究领域。即使经过几十年的深入研究,癌症仍然是一种可怕的疾病,全球发病率不断上升。纳米技术在癌症研究中的进步克服了传统癌症化疗的固有局限性,满足了对靶向药物载体的需求。纳米技术利用恶性细胞改变的病理生理微环境,具有多种优势,如提高溶解度、降低毒性、通过控制释放延长药物循环、规避多药耐药性以及增强生物分布。早期癌症检测对选择最佳药物治疗方案至关重要,因此诊断和治疗是相辅相成的。此外,纳米机器人是一种极具潜力和前景的创新技术,在抗癌和清理血管等方面有着众多重要应用。纳米机器人是一种微小的机器人,大小从 1 纳米到 100 纳米不等。此外,纳米机器人的工作原理与白细胞类似,可以观察血液流动情况并寻找危险迹象。本综述阐述了用作治疗的各种有机和无机纳米粒子和纳米机器人的演变及其利弊。它还强调了诊断方法从传统方法向更先进技术的转变。这一快速发展的领域为设计出理想的纳米粒子提供了更大的空间,使其在治疗和诊断试验中显示出神奇的效果。
{"title":"A Path of Novelty from Nanoparticles to Nanobots: Theragnostic Approach for Targeting Cancer Therapy.","authors":"Gursharanpreet Kaur, Bhawna Khanna, Mohammed Yusuf, Akanksha Sharma, Akhil Khajuria, Hema K Alajangi, Pradeep K Jaiswal, Mandip Sachdeva, Ravi Pratap Barnwal, Gurpal Singh","doi":"10.1615/CritRevTherDrugCarrierSyst.2023046674","DOIUrl":"10.1615/CritRevTherDrugCarrierSyst.2023046674","url":null,"abstract":"<p><p>Pharmaceutical development of cancer therapeutics is a dynamic area of research. Even after decades of intensive work, cancer continues to be a dreadful disease with an ever-increasing global incidence. The progress of nanotechnology in cancer research has overcome inherent limitations in conventional cancer chemotherapy and fulfilled the need for target-specific drug carriers. Nanotechnology uses the altered patho-physiological microenvironment of malignant cells and offers various advantages like improved solubility, reduced toxicity, prolonged drug circulation with controlled release, circumventing multidrug resistance, and enhanced biodistribution. Early cancer detection has a crucial role in selecting the best drug regime, thus, diagnosis and therapeutics go hand in hand. Furthermore, nanobots are an amazing possibility and promising innovation with numerous significant applications, particularly in fighting cancer and cleaning out blood vessels. Nanobots are tiny robots, ranging in size from 1 to 100 nm. Moreover, the nanobots would work similarly to white blood cells, watching the bloodstream and searching for indications of distress. This review articulates the evolution of various organic and inorganic nanoparticles and nanobots used as therapeutics, along with their pros and cons. It also highlights the shift in diagnostics from conventional methods to more advanced techniques. This rapidly growing domain is providing more space for engineering desired nanoparticles that can show miraculous results in therapeutic and diagnostic trials.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"1 1","pages":"1-38"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Critical Reviews in Therapeutic Drug Carrier Systems
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1